Intersurgical recalls breathing systems in Canada across five catalogue numbers over connector failures
Health Canada's Type II notice names 13 lots across CPAP, bilevel and cough-assist circuits, but gives no unit volumes, so the commercial exposure cannot yet be sized.
Intersurgical has begun a Canadian recall covering several of its Smoothbore-based breathing systems, with the financial reach unclear from the public record. Health Canada's notice (RA-82926), published on 6 November 2026, gives a recall date of 28 October but no unit counts, no distribution figures and no description of what the company is asking customers to do.
The stated cause is a manufacturing one. Health Canada says too little tetrahydrofuran solvent was used when the soft connectors were attached to the Smoothbore tubing, leaving some joins weaker than intended. The problem surfaced after field reports of connectors separating from the tube, and the company's testing of its own inventory then confirmed the bond was not secure enough.
Five catalogue numbers are listed. They are a 22mm adult cough-assist system with mask and Flo-Guard (5001011, lot 32510470); two Smoothbore systems (5183000 and 5191000, lots 32527207, 32517823, 32516907 and 32511321); bilevel systems (5805044, lots 32517459, 32518657 and 32515237); and a CPAP system (5804000, lot 32511639). Intersurgical's Canadian address is given as Burlington, Ontario.
The notice is classed as Type II, a category Health Canada generally uses where a product could cause temporary or medically reversible harm, or where the chance of serious harm is considered remote. It reports no injuries. Anyone needing more information is directed to the manufacturer.
Why it matters
- The recall is limited to named lots, so affected hospitals, home-care providers and distributors can check stock against the listed catalogue and lot numbers.
- Because the root cause is a bonding-step quantity, the case bears on process control and manufacturing validation rather than design alone.
- Cost, replacement volumes and any supply impact are not disclosed, so the commercial effect on Intersurgical or its customers cannot be judged from the notice.
Official record: Health Canada ↗
Written by CompePharma's editorial system from the official record. AI-assisted; check the source before acting. Not investment advice.